Stanozolol induces ventricular dysfunction by decreasing phospholamban phosphorylation in heart tissue of LDLr-/- mice

• Autor(a) principal: Andrade, Tadeu Uggere de
• Data de Publicação: 2022
• Outros Autores: Dubois Fillho, Dionisio, Silva, Cristiane Lyrio da, Silva, Mirian de Almeida, Almeida, Simone Alves de, Nascimento, Andrews Marques do, Bissoli, Nazaré Souza, Brasil, Girlandia Alexandre, Lima, Ewelyne Miranda de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/27876
• topic: Anabolic androgenic steroids; Hemodynamic parameters; Cardiac remodeling; Phospholamban phosphorylation.; Esteróide anabolico androgênico; Parâmetros hemodinâmicos; Remodelamento cardíaco; Fosfolambam fosforilada.; Esteroide androgénico anabólico; Parámetros hemodinâmicos; Remodelado cardíaco; Fosfolambano fosforilado.

Stanozolol is a steroid that causes lipid deposition in LDLr-/- mice, although the mechanism by which this dyslipidemia results in cardiac dysfunction is little understood. The aim of this study was to evaluate the effect of stanozolol on cardiac contractility and the participation of myocardial phospholamban (pPLB) phosphorylation in an atherosclerosis mouse model. LDL receptor knockout mice (LDLr-/-) were fed a standard chow diet and received weekly subcutaneous injections of either saline (control, C group) or 20 mg/kg stanozolol (S group). After 8 weeks, hemodynamic parameters were assessed in the left ventricle. The heart was collected, weighted for hypertrophy evaluation, and kept in formalin buffer for morphometric analysis (H&E) and collagen quantification (Picrossirius). Protein expression of PLB and its phosphorylated form (p-PLB) in the left ventricle was determined by western blot. We observed that stanozolol treatment favored cardiac hypertrophy and collagen deposition in heart tissue. Also, stanozolol induced left ventricle dysfunction, increasing PBL expression and decreasing the p-PLB/PLB ratio. Altogether, our data showed that stanozolol causes cardiac remodeling and ventricular dysfunction by decreasing PLB phosphorylation in the left ventricle of LDLr-/- mice.